Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Evaluation and Significance of CD25 Expression in Hematopoietic Stem/Progenitor Cell Fraction of Bone Marrow Cells in Chronic Myelogenous Leukemia Patients

Hidenori Kasahara, MDPhD, Daiki Karigane, MDPhD, Rie Yamazaki, MD, Shinya Fujita, MD, Kouhei Shirosita, MD, Masatoshi Sakurai, MD, Yuya Koda, MD, Taku Kikuchi, MD, Jun Kato, MD, Takayuki Shimizu, MD, Takehiko Mori, MD PhD, Yoko Yatabe, Tomoko Arai, Mitsuru Murata, MDPhD, Hiroshi Kobayashi, MD PhD, Keiyo Takubo, MD PhD, Shinichiro Okamoto, MD PhD

Blood (2018) 132 (Supplement 1): 1723.

https://doi.org/10.1182/blood-2018-99-111586

Published: 2018

Journal Articles

Correlation of Expression of CD25 in Hematopoietic Stem/Progenitor Cell Fraction of Bone Marrow Cells with Response to Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia Patients

Daiki Karigane, MD, Hidenori Kasahara, MD, Masatoshi Sakurai, MD PhD, Eri Matsuki, MD PhD MPH, Keiichi Tozawa, MD, Yuya Koda, MD, Takaaki Toyama, MD, Taku Kikuchi, MD, Jun Kato, MD, Takayuki Shimizu, MD PhD, Takehiko Mori, MD PhD, Yoko Yatabe, Tomoko Arai, Takayuki Mitsuhashi, MD, Mitsuru Murata, MD PhD, Hiroshi Kobayashi, MD PhD, Keiyo Takubo, MD PhD, Shinichiro Okamoto, MD PhD

Blood (2016) 128 (22): 3061.

https://doi.org/10.1182/blood.V128.22.3061.3061

Published: 2016

Journal Articles

Second Attempt to Discontinue TKI in CML Patients Who Have Sustained CMR for over 2 Years Is Rarely Successful Even with the Use of Second Generation TKIs

Eri Matsuki, MD PhD MPH, Masatoshi Sakurai, MD PhD, Daiki Karigane, MD, Hidenori Kasahara, MD, Taku Kikuchi, MD, Takayuki Shimizu, MD PhD, Kenji Yokoyama, MD PhD, Takehiko Mori, MD PhD, Shinichiro Okamoto, MD PhD

Blood (2016) 128 (22): 1887.

https://doi.org/10.1182/blood.V128.22.1887.1887

Published: 2016

Journal Articles

Long-Term Treatment with Imatinib Is Associated with Decreased Estimated Glomerular Filtration Rate and Hemoglobin Level in Patients with Chronic Myelogenous Leukemia

Masatoshi Sakurai, MD PhD, Takehiko Mori, MD PhD, Daiki Karigane, MD, Hidenori Kasahara, MD, Keiichi Tozawa, MD, Eri Matsuki, MD PhD MPH, Taku Kikuchi, MD, Jun Kato, MD, Takayuki Shimizu, MD PhD, Shinichiro Okamoto, MD PhD

Blood (2016) 128 (22): 1888.

https://doi.org/10.1182/blood.V128.22.1888.1888

Published: 2016

Journal Articles

Chemo-Immunotherapy With Hyper-CVAD/MA and Rituximab For B-Cell Lymphomas Leads To Prolonged Immune Suppression Compared To Conventional Treatment With R-CHOP

Eri Matsuki, MD, PhD, Taku Kikuchi, MD, Norisato Hashimoto, MD, Shunsuke Souma, MD, Sumiko Kohashi, MD, Takaaki Toyama, MD, Masatoshi Sakurai, MD, Daiki Karigane, MD, Daichi Abe, MD, Takayuki Shimizu, MD, PhD, Kenji Yokoyama, MD, PhD, Hideaki Nakajima, MD, PhD, Shinichiro Okamoto, MD, PhD

Blood (2013) 122 (21): 1800.

https://doi.org/10.1182/blood.V122.21.1800.1800

Published: 2013

Journal Articles

Molecular Monitoring of ERG and BAALC as Minimal Residual Disease Markers in Patients with Acute Leukemia.

Yuho Najima, MD, Kazuteru Ohashi, MD,FACP, Kazuhiko Kakihana, MD,PhD, Taku Kikuchi, MD, Yasunobu Nagata, MD, Chihiro Sakurai, MD, Toshimitsu Ueki, MD, Takeshi Kobayashi, MD, Takuya Yamashita, MD, Machiko Kawamura, MD,PhD, Hideki Akiyama, MD,PhD, Hidefumi Kaku, MD,PhD, Hisashi Sakamaki, MD,PhD

Blood (2007) 110 (11): 4249.

https://doi.org/10.1182/blood.V110.11.4249.4249

Published: 2007

Journal Articles

Quantitative Monitoring of T315I BCR-ABL Mutation by the Invader Assay.

Kazuhiko Kakihana, MD, PhD, Kazuteru Ohashi, MD, FACP, Yuho Najima, MD, Taku Kikuchi, MD, Yasunobu Nagata, MD, Toshimitsu Ueki, MD, Takeshi Kobayashi, MD, Takuya Yamashita, MD, PhD, Hideki Akiyama, MD, PhD, Toshikazu Yamaguchi, Hisashi Sakamaki, MD, PhD

Blood (2007) 110 (11): 4543.

https://doi.org/10.1182/blood.V110.11.4543.4543

Published: 2007

NARROW

Evaluation and Significance of CD25 Expression in Hematopoietic Stem/Progenitor Cell Fraction of Bone Marrow Cells in Chronic Myelogenous Leukemia Patients

Correlation of Expression of CD25 in Hematopoietic Stem/Progenitor Cell Fraction of Bone Marrow Cells with Response to Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia Patients

Second Attempt to Discontinue TKI in CML Patients Who Have Sustained CMR for over 2 Years Is Rarely Successful Even with the Use of Second Generation TKIs

Long-Term Treatment with Imatinib Is Associated with Decreased Estimated Glomerular Filtration Rate and Hemoglobin Level in Patients with Chronic Myelogenous Leukemia

Chemo-Immunotherapy With Hyper-CVAD/MA and Rituximab For B-Cell Lymphomas Leads To Prolonged Immune Suppression Compared To Conventional Treatment With R-CHOP

Molecular Monitoring of ERG and BAALC as Minimal Residual Disease Markers in Patients with Acute Leukemia.

Quantitative Monitoring of T315I BCR-ABL Mutation by the Invader Assay.

Email alerts

ASH Publications

American Society of Hematology

Evaluation and Significance of CD25 Expression in Hematopoietic Stem/Progenitor Cell Fraction of Bone Marrow Cells in Chronic Myelogenous Leukemia Patients

Correlation of Expression of CD25 in Hematopoietic Stem/Progenitor Cell Fraction of Bone Marrow Cells with Response to Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia Patients

Second Attempt to Discontinue TKI in CML Patients Who Have Sustained CMR for over 2 Years Is Rarely Successful Even with the Use of Second Generation TKIs

Long-Term Treatment with Imatinib Is Associated with Decreased Estimated Glomerular Filtration Rate and Hemoglobin Level in Patients with Chronic Myelogenous Leukemia

Chemo-Immunotherapy With Hyper-CVAD/MA and Rituximab For B-Cell Lymphomas Leads To Prolonged Immune Suppression Compared To Conventional Treatment With R-CHOP

Molecular Monitoring of ERG and BAALC as Minimal Residual Disease Markers in Patients with Acute Leukemia.

Quantitative Monitoring of T315I BCR-ABL Mutation by the Invader Assay.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only